Cancer is a complex multi-factorial disease; its development is triggered by a combination of genetic and environmental factors. Important hereditary factors include mutations in proto-oncogenes, tumor suppressor genes, and DNA damage repair components.
Learn about the validation methods implemented by Bio-Rad, including CRISPR-Cas9 gene editing, siRNA, and immunoprecipitation followed by mass spectrometry, ensuring the specificity and reliability of our antibodies in your application.
Watch the video
Over the past decades much progress has been made in identifying fundamental cancer-predisposing mutations, such as those occurring in members of the BRCA gene family, and developing robust predictive genetic tests. Screening tests, such as mammography and PAP/HPV, have enabled the detection of early stage cancers thereby contributing to the reduction of cancer deaths (NIH 2015).
Although much progress has been made in terms of both cancer treatment and prevention, cancer still remains a global killer. According to the WHO, “Cancers figure among the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases and 8.2 million cancer related deaths in 2012. The number of new cases is expected to rise by about 70% over the next 2 decades (WHO 2015).” Based on these statistics both basic and translational cancer research continue to be of the utmost importance.
In order to assist you with your research, Bio-Rad offers a comprehensive selection of cancer antibodies, cancer PrecisionAb Antibodies for western blotting, Phospho-Specific PrecisionAb Antibodies, proteins, and reagents for all of your research needs.